Aquestive Therapeutics (AQST) Upgraded by Zacks Investment Research to “Buy”

Aquestive Therapeutics (NASDAQ:AQST) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Thursday. The brokerage presently has a $7.75 target price on the stock. Zacks Investment Research‘s price target suggests a potential upside of 11.51% from the stock’s previous close.

According to Zacks, “Aquestive Therapeutics, Inc. is a specialty pharmaceutical company. It commercializes medicines to solve critical health care problems as well as engages on late-stage proprietary product pipeline which focuses on the treatment of diseases of central nervous system. Aquestive Therapeutics, Inc. is based in NJ, United States. “

Other analysts have also issued research reports about the company. BMO Capital Markets decreased their price objective on Aquestive Therapeutics from $24.00 to $21.00 and set an “outperform” rating on the stock in a report on Friday, March 15th. Lake Street Capital reissued a “buy” rating on shares of Aquestive Therapeutics in a report on Wednesday, February 20th. Finally, Wedbush set a $30.00 price objective on Aquestive Therapeutics and gave the stock a “buy aqst” rating in a report on Thursday, December 20th. Five research analysts have rated the stock with a buy rating, Aquestive Therapeutics has an average rating of “Buy” and an average price target of $20.96.

AQST traded down $0.03 during midday trading on Thursday, reaching $6.95. The company’s stock had a trading volume of 51,285 shares, compared to its average volume of 118,534. The firm has a market capitalization of $174.36 million and a P/E ratio of -2.48. The company has a quick ratio of 2.09, a current ratio of 2.25 and a debt-to-equity ratio of 4.23. Aquestive Therapeutics has a twelve month low of $5.60 and a twelve month high of $20.70.

Aquestive Therapeutics (NASDAQ:AQST) last released its earnings results on Thursday, March 14th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.91) by $0.35. The business had revenue of $16.82 million during the quarter, compared to analyst estimates of $17.05 million. As a group, analysts anticipate that Aquestive Therapeutics will post -3.19 earnings per share for the current year.

Several institutional investors have recently bought and sold shares of AQST. New York State Common Retirement Fund bought a new position in shares of Aquestive Therapeutics during the 4th quarter worth approximately $28,000. Bank of New York Mellon Corp bought a new position in shares of Aquestive Therapeutics during the 4th quarter worth approximately $108,000. Millennium Management LLC bought a new position in shares of Aquestive Therapeutics during the 4th quarter worth approximately $145,000. Squarepoint Ops LLC bought a new position in shares of Aquestive Therapeutics during the 4th quarter worth approximately $188,000. Finally, Keybank National Association OH bought a new position in shares of Aquestive Therapeutics during the 3rd quarter worth approximately $239,000. Institutional investors and hedge funds own 57.62% of the company’s stock.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc, a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. Its products are developed using its PharmFilm technology. The company's marketed products include Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron antagonist for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery.

Featured Article: Cost of Capital

Get a free copy of the Zacks research report on Aquestive Therapeutics (AQST)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.